Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol

BACKGROUND: In the management of patients with RAS wild-type metastatic colorectal cancer (mCRC), anti-epidermal growth factor receptor (EGFR) therapies have demonstrated a clinical benefit, with longer survival. However, the correlation between the emergence of circulating RAS mutations and seconda...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shang-Hung, Tsai, Hsiang-Lin, Jiang, Jeng-Kai, Sung, Yung-Chuan, Huang, Ching-Wen, Yeh, Yu-Min, Chen, Li-Tzong, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599252/
https://www.ncbi.nlm.nih.gov/pubmed/31253124
http://dx.doi.org/10.1186/s12885-019-5826-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599252/
https://www.ncbi.nlm.nih.gov/pubmed/31253124
http://dx.doi.org/10.1186/s12885-019-5826-7

Ejemplares similares